Alzheimer Scotland criticises drug research

Alzheimer Scotland has criticised research findings published today in The Lancet. The study by the AD2000 Collaborative Group at The University of Birmingham Clinical Trials Unit states that the dementia drug donepezil (read Alzheimer Scotland information sheet: Aricept or donepezil hydrochloride) is not cost effective and has marginal benefits for people with mild to moderate Alzheimer’s disease.

Jim Jackson, Chief Executive, Alzheimer Scotland, said:

’‘Alzheimer Scotland criticises the study carried out by the AD2000 Collaborative Group based on three key factors:

1) The study was methodologically flawed and did not take into account what was already known about this treatment.
2) The study failed to investigate the impact of the benefits to patients for whom the drug works.
3) We know that donepezil is not a wonder drug but it and the other cholinesterase inhibitors are all we have at present. We must not remove the hope that this treatment brings.’’

Mr Jackson continued,
‘‘Alzheimer Scotland encourages doctors to continue prescribing this treatment where in their clinical judgement patients are benefiting. Alzheimer Scotland also wants doctors to continue to prescribe donepezil in line with the Health Technology Board for Scotland’s guidance.’’

ENDS

CASE STUDIES AND INTERVIEWS ARE AVAILABLE

24 hour Dementia Helpline
Freephone 0808 808 3000

Alzheimer Scotland - Action on Dementia is a company limited by guarantee, registered in Scotland 149069. Registered Office: 22 Drumsheugh Gardens, Edinburgh EH3 7RN. It is recognised as a charity by the Office of the Scottish Charity Regulator, no. SC022315.